A new study examines how cost, side effects and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

Obesity is a growing concern worldwide, including in low- and middle-income countries (LMICs). Addressing this issue involves various strategies, including dietary and lifestyle changes, medical ...

The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...

Biomed Industrie, Inc. logo NA-931 for weight loss Biomed pipeline Biomed Industries, Inc. Engages with Medicare to Advan ...

Moreover, the stigma surrounding obesity disproportionately affects lower-income individuals, who are often blamed for their ...

Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

Major stock indexes closed lower on Friday, after the week saw a flurry of events, including DeepSeek scare and earnings ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

In recent years, there have been more developments in the area of diabetes management, with the emergence of metformin and more recently semaglutide ... to cost the US economy $327 billion per ...